HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hartz, R. S. Articles by Michaelis, L. L. Search for Related Content PubMed PubMed Citation Articles by Hartz, R. S. Articles by Michaelis, L. L.

The Journal of Thoracic and Cardiovascular Surgery, Vol 92, 684-690, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position

RS Hartz, J LoCicero 3d, V Kucich, A DeBoer, S O'Mara, SN Meyers and LL Michaelis

To determine the necessity of long-term warfarin anticoagulation after St. Jude Medical aortic valve replacement in adults, we evaluated the risks of thromboembolism, valve thrombosis, anticoagulant hemorrhage, and sudden cardiac death in two groups of patients. Group I consisted of 41 patients treated with conventional long-term warfarin therapy. Forty-two patients in Group II were treated primarily with antiplatelet therapy (aspirin, dipyridamole, or both); 17 of these patients received warfarin for a short time postoperatively and seven others received it intermittently during the study period. The groups were similar with respect to age, sex, associated cardiovascular disease, and length of follow-up (mean 29 months per patient). In the warfarin-treated group, three late sudden deaths occurred, one of which was preceded by a cerebrovascular accident, for a cardiac mortality of 2.7% per patient- year. There were eight major nonfatal complications (7.3% per patient- year), of which four were hemorrhagic and four embolic. In Group II, there was one sudden cardiac death (1.1% per patient-year) and four major complications occurred (3.2% per patient-year). Two of the complications were embolic and two were episodes of valve thrombosis, both necessitating reoperation. Although the incidence of serious morbidity in the warfarin-treated group was twice that of patients treated with antiplatelet therapy, there were no statistically significant differences in the rates of sudden death or major complications. These data suggest that antiplatelet therapy may be as effective as warfarin in preventing embolism from the St. Jude Medical valve in the aortic position. Valve thrombosis occurred in two patients, both receiving antiplatelet therapy (2.2% per patient-year). Whether this type of valve failure can be prevented by warfarin remains in question.

This article has been cited by other articles:

				S. H. McKellar, J. L. Thompson III, R. F. Garcia-Rinaldi, R. J. MacDonald, T. M. Sundt III, and H. V. Schaff Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 908 - 914. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]

				R. W. Emery, A. M. Emery, A. Knutsen, and G. V. Raikar Aortic Valve Replacement with a Mechanical Cardiac Valve Prosthesis Card. Surg. Adult, January 1, 2008; 3(2008): 841 - 856. [Full Text]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]

				M. K. Pasque and J. G. Rogers Adverse events in the use of HeartMate vented electric and Novacor left ventricular assist devices: Comparing apples and oranges J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1063 - 1067. [Full Text]

				P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves Chest, January 1, 2001; 119(1_suppl): 220S - 227S. [Full Text] [PDF]

				J. Acar, B. Iung, J. P. Boissel, M. M. Samama, P. L. Michel, J. P. Teppe, J. C. Pony, H. Le Breton, D. Thomas, R. Isnard, et al. AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart Valves Circulation, November 1, 1996; 94(9): 2107 - 2112. [Abstract] [Full Text]

				H. Pouleur and M. Buyse EFFECTS OF DIPYRIDAMOLE IN COMBINATION WITH ANTICOAGULANT THERAPY ON SURVIVAL AND THROMBOEMBOLIC EVENTS IN PATIENTS WITH PROSTHETIC HEART VALVESA meta-analysis of the randomized trials J. Thorac. Cardiovasc. Surg., August 1, 1995; 110(2): 463 - 472. [Abstract] [Full Text]